Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT03838926 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Tolerability Study of Trichostatin A In Subjects With Relapsed or Refractory Hematologic Malignancies

StatusRecruiting
PhasePhase 1
Started2018-09-27
View on ClinicalTrials.gov ↗

Amendment history

2026-03-12
Study Status, Oversight, Contacts/Locations, IPDSharing v3
Primary completion date2025-12→2027-12
Completion date2025-12→2027-12
Study sitesdetails revised at 3 of 11 sites
2025-07-14
Study Status, Oversight, Contacts/Locations, IPDSharing v2
Primary completion date2020-08→2025-12
Completion date2020-09→2025-12
Study sites5→11
2019-02-11
Study Status, Eligibility v1
Eligibility criteria+1 characters
[...] pproved avoidance of pregnancy measures Exclusion Criteria: AllogenicAllogeneic stem cell transplant recipient presenting with graft versus [...]
2019-02-11
Original filing
The aim of this study is to investigate the safety and tolerability of trichostatin A in individuals with relapsed or refractory hematologic malignancies.
Trial Details
NCT Number NCT03838926
Lead Sponsor Vanda Pharmaceuticals
Conditions Relapsed or Refractory Hematologic Malignancies
Enrollment 42 participants
Start Date 2018-09-27
Primary Completion 2027-12 (estimated)
Study Completion 2027-12 (estimated)
Updated on ClinicalTrials.gov 2026-03-16